Literature DB >> 22409246

Psychometric evaluation of the HIV symptom distress scale.

Linda G Marc1, Ming-Mei Wang, Marcia A Testa.   

Abstract

The objective of this article is to psychometrically validate the HIV symptom distress scale (SDS), an instrument that can be used to measure overall HIV symptom distress or clinically relevant groups of HIV symptoms. A secondary data analysis was conducted using the Collaborations in HIV Outcomes Research US Cohort (CHORUS). Inclusion criteria required study participants (N=5521) to have a valid baseline measure of the AIDS Clinical Trial Group Symptom Distress Module, with an SF-12 or SF-36 completed on the same day. Psychometric testing assessed unidimensionality, internal consistency, and factor structure using exploratory and confirmatory factor analysis, and structural equation modeling (SEM). Construct validity examined whether the new measure discriminates across clinical significance (CD4 and HIV viral load). Findings show that the SDS has high reliability (α=0.92), and SEM supports a correlated second-order factor model (physical and mental distress) with acceptable fit (GFI=0.88, AGFI=0.85, NFI=0.99, NNFI=0.99; RMSEA=0.06, [90% CI 0.06 - 0.06]; Satorra Bentler scaled, C (2) =3274.20; p=0.0). Construct validity shows significant differences across categories for HIV-1 viral load (p<0.001) and CD4 (p<0.001). Differences in mean SDS scores exist across gender (p<0.001), race/ethnicity (p<0.05), and educational attainment (p<0.001). Hence, the HIV SDS is a reliable and valid instrument, which measures overall HIV symptoms or clinically relevant groups of symptoms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22409246      PMCID: PMC3436989          DOI: 10.1080/09540121.2012.656567

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  21 in total

1.  Socio-economic factors and health-related quality of life in adults living with HIV.

Authors:  C Worthington; H B Krentz
Journal:  Int J STD AIDS       Date:  2005-09       Impact factor: 1.359

Review 2.  Methodological issues in determining the dimensionality of composite health measures using principal component analysis: case illustration and suggestions for practice.

Authors:  Joël Coste; Stéphane Bouée; Emmanuel Ecosse; Alain Leplège; Jacques Pouchot
Journal:  Qual Life Res       Date:  2005-04       Impact factor: 4.147

3.  Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment.

Authors:  B Gandek; J E Ware; N K Aaronson; G Apolone; J B Bjorner; J E Brazier; M Bullinger; S Kaasa; A Leplege; L Prieto; M Sullivan
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

Review 4.  Methods for quality-of-life studies.

Authors:  M A Testa; J F Nackley
Journal:  Annu Rev Public Health       Date:  1994       Impact factor: 21.981

5.  Gender differences in health-related quality of life in patients with HIV/AIDS.

Authors:  Joseph M Mrus; Paige L Williams; Joel Tsevat; Susan E Cohn; Albert W Wu
Journal:  Qual Life Res       Date:  2005-03       Impact factor: 4.147

Review 6.  Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV).

Authors:  A W Wu; D A Revicki; D Jacobson; F E Malitz
Journal:  Qual Life Res       Date:  1997-08       Impact factor: 4.147

7.  Measuring quality of life in early HIV disease: the modular approach.

Authors:  W R Lenderking; M A Testa; D Katzenstein; S Hammer
Journal:  Qual Life Res       Date:  1997-08       Impact factor: 4.147

Review 8.  Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS.

Authors:  A W Wu; R D Hays; S Kelly; F Malitz; S A Bozzette
Journal:  Qual Life Res       Date:  1997-08       Impact factor: 4.147

9.  A Perceived Health Index for use in persons with advanced HIV disease: derivation, reliability, and validity.

Authors:  S A Bozzette; R D Hays; S H Berry; D E Kanouse
Journal:  Med Care       Date:  1994-07       Impact factor: 2.983

10.  An index of symptoms for infection with human immunodeficiency virus: reliability and validity.

Authors:  C C Whalen; M Antani; J Carey; C S Landefeld
Journal:  J Clin Epidemiol       Date:  1994-05       Impact factor: 6.437

View more
  8 in total

1.  Sexual Dysfunction in Men With Inflammatory Bowel Disease: A New IBD-Specific Scale.

Authors:  Aoibhlinn O'Toole; Punyanganie S de Silva; Linda G Marc; Christine A Ulysse; Marcia A Testa; Amanda Ting; Alan Moss; Josh Korzenik; Sonia Friedman
Journal:  Inflamm Bowel Dis       Date:  2018-01-18       Impact factor: 5.325

2.  Medication Adherence and HIV Symptom Distress in Relation to Panic Disorder Among HIV-Positive Adults Managing Opioid Dependence.

Authors:  Jesse D Kosiba; Adam Gonzalez; Conall O'Cleirigh; Steven A Safren
Journal:  Cognit Ther Res       Date:  2014-08

3.  Uptake to HIV post-exposure prophylaxis in Haiti: opportunities to align sexual violence, HIV PEP and mental health.

Authors:  Linda Marc; Jean-Guy Honoré; Patrick Néjuste; Monica Setaruddin; Nika-Nola Lamothe; Gabriel Thimothé; Jean-Ronald Cornely
Journal:  Am J Reprod Immunol       Date:  2012-12-28       Impact factor: 3.886

4.  Reliability and validity of the Haitian Creole PHQ-9.

Authors:  Linda G Marc; Whitney R Henderson; Astrid Desrosiers; Marcia A Testa; Samuel E Jean; Eniko Edit Akom
Journal:  J Gen Intern Med       Date:  2014-08-05       Impact factor: 5.128

5.  Development of a Sexual Dysfunction Scale for Women With Inflammatory Bowel Disease.

Authors:  Punyanganie S de Silva; Aoibhlinn O'Toole; Linda G Marc; Christine A Ulysse; Marcia A Testa; Mette Julsgaard; Deanna Ngyuen; Ashwin Ananthakrishnan; Tine Laursen; Astrid Højgaard; Lisbet A Christensen; Joshua Korzenik; Sonia Friedman
Journal:  Inflamm Bowel Dis       Date:  2018-10-12       Impact factor: 5.325

6.  Protocol of the randomized control trial: the WiseApp trial for improving health outcomes in PLWH (WiseApp).

Authors:  Gabriella Flynn; Haomiao Jia; Nancy R Reynolds; David C Mohr; Rebecca Schnall
Journal:  BMC Public Health       Date:  2020-11-25       Impact factor: 3.295

7.  Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression.

Authors:  Andrea Antinori; Maria V Cossu; Barbara Menzaghi; Gaetana Sterrantino; Nicola Squillace; Valentina Di Cristo; Annamaria Cattelan; Emanuele Focà; Antonella Castagna; Giancarlo Orofino; Daniela Valenti; Gabriella D'Ettore; Lucia Aprea; Sergio Ferrara; Maria E Locatelli; Giordano Madeddu; Emanuele Pontali; Paolo Scerbo; Barbara Rossetti; Alessia Uglietti; Roberta Termini; Francesco Rucci; Andrea Gori; Daniela Mancusi
Journal:  Patient       Date:  2020-06       Impact factor: 3.883

8.  Patient Satisfaction with Once-Daily Single-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (DRV/c/FTC/TAF): A Real-World Study of Patient Self-Reported Outcomes in HIV-1-Diagnosed Adults.

Authors:  Joyce LaMori; Antoine Seignez; Lise Radoszycki
Journal:  Patient Prefer Adherence       Date:  2022-01-13       Impact factor: 2.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.